Biomarin Pharmaceutical Inc (NASDAQ:BMRN)
| 117.27 Delayed Data As of Jan 27 |  +0.29 / +0.25%Today’s Change | 70.73 Today|||52-Week Range 117.77 | +13.32% Year-to-Date |
Latest BMRN News | Press Releases
| Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last? Jan 25 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 116.98 |
| Today’s open | 117.00 |
| Day’s range | 116.81 - 117.77 |
| Volume | 1,217,219 |
| Average volume (3 months) | 1,455,560 |
| Market cap | $21.8B |
Data as of 3:59pm ET, 01/27/2023
Growth & Valuation
| Earnings growth (last year) | -107.37% |
| Earnings growth (this year) | +303.16% |
| Earnings growth (next 5 years) | +1.50% |
| Revenue growth (last year) | +0.20% |
| P/E ratio | 272.7 |
| Price/Sales | 8.75 |
| Price/Book | 5.05 |
Competitors
Data as of 3:59pm ET, 01/27/2023
Financials
| Next reporting date | February 22, 2023 |
| EPS forecast (this quarter) | -$0.06 |
| Annual revenue (last year) | $1.8B |
| Annual profit (last year) | -$64.1M |
| Net profit margin | -3.47% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Rafael, California |
Forecasts
